FrancophonIA/ELRC3.0 huggingface dataset:
English: A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data from 21 patients.
Maltese: Studju dwar interazzjoni bejn mediċina u oħra li evalwa l-effett ta' melphalan-prednisone fuq ilfarmakokinetika ta' bortezomib (injettat ġol-vini) wera żieda medja fl-AUC ta' 17% abbażi ta' dejta minn 21 pazjent.
English: Bortezomib was positive for clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary (CHO) cells at concentrations as low as 3.125 μg/ml, which was the lowest concentration evaluated.
Maltese: Bortezomib kien pożittiv għall-attività klastoġenika (aberrazzjonijiet fl-istruttura tal-kromożomi) flanaliżi in vitro għal aberrazzjonijiet kromosomali bl-użu ta' ċelluli tal-ovarju tal-ħamster Ċiniż (CHO) anki b'konċentrazzjonijiet baxxi ta' 3.125 μg/ml, li kienet l-iċken konċentrazzjoni li kienet evalwata.
English: Bzmb+M+P n=344
Maltese: Bzmb+M+P
English: Efficacy results are presented in Table 16:
Maltese: Tabella 16:
English: Patients who developed orthostatic hypotension on bortezomib (injected intravenously) did not have evidence of orthostatic hypotension prior to treatment with bortezomib.
Maltese: Pazjenti li żviluppaw ipotensjoni ortostatika b'bortezomib (injettat ġol-vini) ma kellhomx evidenza ta' ipotensjoni ortostatika qabel ma kienu bdew it-trattament b'bortezomib.
English: Common Sepsis (inc septic shock)*, Herpes zoster (inc disseminated & ophthalmic), Herpes virus infection*, Bacterial infections*, Upper/lower respiratory tract infection*, Fungal infection*, Herpes simplex* Uncommon Hepatitis B, Infection*, Bronchopneumonia
Maltese: Sepsi (inkluż xokk settiku)*, Herpes zoster (inkluż mifrux u tal-għajn), Infezzjoni bil-virus tal-herpes*, Infezzjonijiet bil-batterji*, Infezzjoni fil-passaġġ tannaħa ta' fuq/ta' taħt tan-nifs*, Infezzjoni bil-fungu*, Herpes simplex*
English: Bortezomib SUN dose should be reduced by 1 dose level (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2)
Maltese: Imbagħad Bortezomib SUN jista' jerġa' jinbeda bi tnaqqis ta' livell 1 tad-doża (minn 1.3 mg/m2 għal 1 mg/m2, jew minn 1 mg/m2 għal 0.7 mg/m2).
English: The median duration of treatment was 24.0 weeks and the median number of treatment cycles received was 6.0, and was consistent across treatment groups.
Maltese: It-tul ta' żmien medjan ta' trattament kien ta' 24.0 ġimgħa u n-numru medjan ta' ċikli ta' trattament li ngħataw kien ta' 6.0, u dan kien konsistenti fil-gruppi kollha ta' trattament.
English: Management of orthostatic/postural hypotension may include adjustment of antihypertensive medicinal products, rehydration or administration of mineralocorticosteroids and/or sympathomimetics.
Maltese: It-trattament tal-ipotensjoni ortostatika/tal-qagħda jista' jinkludi bdil fid-doża ta' prodotti mediċinali kontra l-ipertensjoni, idratazzjoni mill-ġdid jew ilgħoti ta' mineralokortikosterojdi u/jew simpatomimetiċi.
English: Dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib SUN 21-day treatment cycle.
Maltese: Dexamethasone 40 mg jingħata mill-ħalq f'jiem 1, 2, 3, 4, 8, 9, 10, u 11 taċ-ċiklu ta' trattament ta' Bortezomib SUN ta' 21 jum.
English: Up to 8 cycles of this combination therapy can be administered as long as patients have not progressed and tolerate treatment.
Maltese: Sa 8 ċikli ta' din it-terapija kombinata jistgħu jingħataw kemm-il darba l-kundizzjoni fil-pazjent ma kunx ipprogressat u t-trattament jiġi ttollerat.
English: 1.1 Preparation of the 3.5 mg vial: carefully add 1.4 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the Bortezomib SUN powder by using a syringe of the appropriate size without removing the vial stopper.
Maltese: 1.1 Preparazzjoni tal-kunjett ta' 3.5 mg: b'attenzjoni żid 1.4 ml ta' 9 mg/ml (0.9%) ta' soluzzjoni sterili ta' sodium chloride għall-injezzjoni fil-kunjett li fih it-trab Bortezomib SUN billi tuża siringa tad-daqs xieraq mingħajr ma tneħħi t-tapp tal-kunjett.
English: Phase II study MMY-2036 (RETRIEVE), single arm, open-label study was conducted to determine the efficacy and safety of retreatment with bortezomib.
Maltese: L-istudju ta' Fażi II MMY-2036 (RETRIEVE) kien ta' grupp wieħed, open-label, sar biex jistabbilixxi l-effikaċja u s-sigurtà ta' trattament mill-ġdid b'bortezomib.
English: Normal liver function should be confirmed and caution should be exercised in patients receiving oral hypoglycemics (see section 4.5).
Maltese: Għandu jiġi kkonfermat li l-funzjoni tal-fwied tkun normali u kawtela għandha tiġi eżerċitata f'pazjenti li jkunu qed jirċievu ipogliċemiċi orali (ara sezzjoni 4.5).
English: The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites.
Maltese: Il-mogħdija metabolika maġġuri hija d-deboronazzjoni biex jiġu ffurmati żewġ metaboliti deboronizzati li wara jgħaddu minn proċess ta' idrossilazzjoni għal diversi metaboliti.
English: Grade 4 (life-threatening consequences; urgent intervention indicated) and/or severe autonomic neuropathy
Maltese: Grad 4 (konsegwenzi li jistgħu jkunu ta' thedida għall-ħajja; intervent urġenti indikat) u/jew newropatija awtonomika severa
English: BzmbR-CAP=bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy
Maltese: R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, u prednisone; PN= newropatija periferali
English: Refer to the Summary of Product Characteristics of thalidomide for additional information.
Maltese: Irreferi għas-Sommarju tal-Karatteristiċi talProdott ta' thalidomide għal aktar informazzjoni.
English: CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bzmb=bortezomib; BzmbTDx=bortezomib, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response;
Maltese: ITT=intent to treat - maħsub għal trattament; RR=response rate - rata ta rispons; Bzmb=bortezomib;
English: • different reconstitution requirements for intravenous (IV) or subcutaneous (SC) use
Maltese: • ħtiġijiet ta' rikostituzzjoni differenti għall-użu ġol-fina (IV) jew taħt il-ġilda (SC)
English: You may also be given Bortezomib SUN together with the medicines pegylated liposomal doxorubicin or dexamethasone: - When Bortezomib SUN is given together with pegylated liposomal doxorubicin, you will receive Bortezomib SUN intravenously or subcutaneously as a 21-day treatment cycle.
Maltese: Meta Bortezomib SUN jingħata f'kombinazzjoni ma' prodotti mediċinali oħra, is-Sommarji talKaratteristiċi tal-Prodott ta' dawn il-prodotti mediċinali l-oħra għandhom jiġu kkonsultati qabel ilbidu tat-trattament b'Bortezomib SUN.
English: Thalidomide is administered orally at 50 mg daily on days 1-14 and if tolerated the dose is increased to 100 mg on days 15-28, and thereafter may be further increased to 200 mg daily from cycle 2 (see Table 4).
Maltese: Thalidomide jingħata mill-ħalq f'doża ta' 50 mg kuljum f'jiem 1-14 u jekk jiġi ttolerat id-doża għandha tiżdied għal 100 mg f'jiem 15-28, u wara dan tista' tiżdied aktar għal 200 mg kuljum minn ċiklu 2 (ara Tabella 4).
English: 13.1 mo
Maltese: 13.1 xahar
English: Each carton of Bortezomib SUN 3.5 mg powder for solution for injection contains a clear glass 10 ml vial closed with a light green aluminium cap, in a transparent blister pack.
Maltese: Kull kartuna ta' Bortezomib SUN 3.5 mg trab għal soluzzjoni għall-injezzjoni fiha kunjett tal-ħġieġ ċar ta' 10 ml, magħluq b'għatu tal-aluminju aħdar ċar, f'pakkett b'folji trasparenti.
English: For additional information concerning melphalan and prednisone, see the corresponding Summary of Product Characteristics.
Maltese: Għal aktar informazzjoni dwar melphalan u prednisone, ara s-Sommarju tal-Karatteristiċi tal-Prodott korrispondenti.
English: Hepatitis B Virus (HBV) reactivation and infection When rituximab is used in combination with bortezomib, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment.
Maltese: Attivazzjoni mill-ġdid u infezzjoni bil-Virus tal-Epatite B (HBV - Hepatitis B Virus) Meta rituximab jintuża flimkien ma' bortezomib, għandu dejjem isir ittestjar għal HBV f'pazjenti b'riskju ta' infezzjoni b'HBV qabel il-bidu tat-trattament.
English: - Keep this leaflet.
Maltese: Proporzjon ta' periklub
English: - Non-haematological toxicities should have resolved to Grade 1 or baseline Table 3: Posology modifications during subsequent cycles of Bortezomib SUN therapy in combination with melphalan and prednisone
Maltese: Tabella 3: Modifikazzjonijiet fil-pożoloġija waqt ċikli sussegwenti ta' terapija b'Bortezomib SUN flimkien ma' melphalan u prednisolone
English: Macrophage activation
Maltese: Attivazzjoni tal-makrofagu
English: Pancreatitis acute, Peritonitis*, Tongue oedema*, Ascites, Oesophagitis, Cheilitis, Faecal incontinence, Anal sphincter atony, Faecaloma*, Gastrointestinal ulceration and perforation*, Gingival hypertrophy, Megacolon, Rectal discharge, Oropharyngeal blistering*, Lip pain, Periodontitis, Anal fissure, Change of bowel habit, Proctalgia, Abnormal faeces
Maltese: Pankreatite akuta, Peritonite*, Edema tal-ilsien*, Axxite, Esofagite, Ċejlite, Inkontinenza tal-ippurgar, Atonija flisphincter anali, Fekaloma*, Ulċerazzjoni u perforazzjoni gastrointestinali*, Ipertrofija ġinġivali, Megakolon, Tnixxija rektali, Infafet orofarinġeali*, Uġigħ fixxufftejn, Perjodontite, Qasma anali, Bidla fil-mod ta' kif u meta tipporga, Proktalġja, Ippurgar mhux normali
English: Overall, bortezomib was administered for the treatment of multiple myeloma in 3,974 patients.
Maltese: B'kollox, bortezomib ġie mogħti lil 3,974 pazjent għat-trattament ta' majeloma multipla.
English: Bortezomib mediated proteasome inhibition affects cancer cells in a number of ways, including, but not limited to, altering regulatory proteins, which control cell cycle progression and nuclear factor kappa B (NF-kB) activation.
Maltese: L-inibizzjoni tal-proteasome permezz ta' bortezomib taffettwa ċ-ċelluli tal-kanċer b'diversi modi, inkluż, imma mhux limitat, għall-bdil tal-proteini regolatorji, li jikkontrollaw iċ-ċiklu tal-progressjoni taċ-ċellula u l-attivazzjoni tal-fattur nukleari kappa B (NF-kB).
English: Frequencies are defined as: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100);
Maltese: Komuni ħafna (≥ 1/10); komuni (≥ 1/100 sa < 1/10); mhux komuni (≥ 1/1,000 sa < 1/100); rari (≥ 1/10,000 sa < 1/1,000); rari ħafna (< 1/10,000), mhux magħruf (ma tistax tittieħed stima mid-dejta disponibbli).
English: In the Phase III study patients who received bortezomib subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were Grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of bortezomib.
Maltese: III, pazjenti li ħadu bortezomib taħt il-ġilda meta paragunati ma' dawk li ħaduh ġolvini kellhom inċidenza globali ta' 13% inqas ta' reazzjonijiet avversi li rriżultaw mit-trattament li kienu ta' grad 3 jew ogħla fit-tossiċità, u inċidenza inqas ta' 5% ta' waqfien b'bortezomib.
English: g P-value from the Cochran Mantel-Haenszel chi-square test, with IPI and stage of disease as stratification factors.
Maltese: g Valur p mit-test chi-squared ta' Cochran Mantel-Haenszel, bir-riskju IPI u l-istadju tal-marda bħala fatturi ta'
English: or ANC < 750 cells/μl on a Bortezomib SUN dosing day (other than Day 1 of each cycle)
Maltese: jew l-ANC ikun < 750 ċellula/μL f'jum ta' għoti ta' doża ta' Bortezomib SUN (ħlief f'jum 1 ta' kull ċiklu)
English: Previously untreated multiple myeloma
Maltese: Majeloma multipla mhux ittrattata minn qabel
English: Rhabdomyolysis, Temporomandibular joint syndrome, Fistula, Joint effusion, Pain in jaw, Bone disorder, Musculoskeletal and connective tissue infections and inflammations*, Synovial cyst
Maltese: Rabdomijolisi, Sindrome tal-ġog temporomandibulari, Fistula, Effużjoni tal-ġog, Uġigħ fix-xedaq, Disturb talgħadam, Infezzjonijiet u infjammazzjonijiet muskuloskeletriċi u tat-tessut konnettiv*, Ċista sinovjali
English: Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia* Uncommon Pancytopenia*
Maltese: Tromboċitopenija*, Newtropenija bid-deni, Newtropenija*, Lewkopenija*, Anemija*, Limfopenija*
English: Dexamethasone 40 mg is given orally on days-1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib SUN 28-day treatment cycle.
Maltese: Dexamethasone 40 mg jingħata mill-ħalq f'jiem 1, 2, 3, 4, 8, 9, 10, u 11 taċ-ċiklu ta' trattament ta' Bortezomib SUN ta' 28 jum.
English: The solution will be clear and colourless, with a final pH of 4 to 7.
Maltese: Is-soluzzjoni hija transparenti u bla kulur, b'pH finali ta' bejn 4 u 7.
English: Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Maltese: Bortezomib SUN flimkien ma' rituximab, cyclophosphamide, doxorubicin u prednisone huwa indikat għat-trattament ta' pazjenti adulti b'limfoma taċ-ċelluli mantle li qatt ma kienu ttrattati qabel li mhumiex addattati għal trapjant ta' ċelluli staminali ematopojetiċi.
English: Thrombocytopenia*, Neutropenia*, Anaemia* Common Leukopenia*, Lymphopenia* Uncommon Pancytopenia*, Febrile neutropenia, Coagulopathy*, Leukocytosis*, Lymphadenopathy, Haemolytic anaemia#
Maltese: Panċitopenija*, Newtropenija bid-deni, Koagulopatija*, Lewkoċitożi*, Limfodenopatija, Anemija emolitika#
English: e Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors.
Maltese: e Qed tintuża l-istima Mantel-Haenszel tal-proporzjon ta' probabbiltà komuni għal tabelli stratifikati, bir-riskju IPI u l-istadju tal-marda bħala fatturi ta' stratifikazzjoni.
English: Common Motor neuropathy*, Loss of consciousness (inc syncope), Dizziness*, Dysgeusia*, Lethargy, Headache* Uncommon Tremor, Peripheral sensorimotor neuropathy, Dyskinesia*, Cerebellar coordination and balance disturbances*, Memory loss (exc dementia)*, Encephalopathy*, Posterior Reversible Encephalopathy Syndrome#, Neurotoxicity, Seizure disorders*, Post herpetic neuralgia, Speech disorder*, Restless legs syndrome, Migraine, Sciatica, Disturbance in attention, Reflexes abnormal*, Parosmia
Maltese: Rogħda, Newropatija sensomotorili periferali, Diskinesija*, Disturbi fil-bilanċ u fil-koordinazzjoni ċerebellari*, Telf ta' memorja (li jeskludi dimenzja)*, Enċefalopatija*, Sindrome Enċefalopatiku Riversibbli fuq Wara#, Newrotossiċita, Disturbi pupletiċi*, Newralġja post erpetika, Disturb fid-diskors*, Sindrome ta' irrikwitezza fir-riġlejn, Emigranja, Xjatika, Disturb flattenzjoni, Anormalita fir-riflessi*, Parosmija
English: With a median duration of follow-up of 40 months, median OS (56.3 months in the R-CHOP group, and not reached in the BzmbR-CAP group) favoured the BzmbR-CAP group, (estimated HR=0.80; p=0.173).
Maltese: B'tul medjan ta' żmien ta' follow-up ta' 40 xahar, il-medjan ta' OS (56.3 xhur fil-grupp ta' R-CHOP, u ma ntlaħaqx fil-grupp ta' BzmbR-CAP) iffavorixxa l-grupp ta' BzmbR-CAP, (stima ta' HR=0.80; p=0.173).
English: Bortezomib SUN treatment must be withheld at the onset of any ≥ Grade 3 bortezomib-related non-haematological toxicities (excluding neuropathy) or ≥ Grade 3 haematological toxicities (see also section .4).
Maltese: It-trattament b'Bortezomib SUN għandu jitwaqqaf mal-bidu ta' kwalunkwe tossiċitajiet mhux ematoloġiċi (minbarra newropatija) ta' ≥ Grad 3 marbuta ma' bortezomib jew tossiċitajiet ematoloġiċi ta' ≥ Grad 3 (ara wkoll sezzjoni 4.4).
English: Bortezomib causes reduction of tumour growth in vivo in many preclinical tumour models, including multiple myeloma.
Maltese: Bortezomib inaqqas it-tkabbir tat-tumur in vivo f'ħafna mudelli tumorali prekliniċi, inkluż il-majeloma multipla.
English: Bortezomib combination treatment with dexamethasone In the absence of any direct comparison between bortezomib and bortezomib in combination with dexamethasone in patients with progressive multiple myeloma, a statistical matched-pair analysis was conducted to compare results from the non randomised arm of bortezomib in combination with dexamethasone (Phase II open-label study MMY-2045), with results obtained in the bortezomib monotherapy arms from different Phase III randomised studies (M34101-039 [APEX] and DOXIL MMY-3001) in the same indication.
Maltese: Trattament kombinat ta' bortezomib ma' dexamethasone Fin-nuqqas ta' paragun dirett bejn bortezomib u bortezomib f'kombinazzjoni ma' dexamethasone f'pazjenti b'majeloma multipla progressiva, saret analiżi statistika ta' tqabbil bejn pari sabiex isir paragun bejn riżultati mill-parti tal-istudju dwar parteċipanti li ma ntgħażlux b'mod każwali li kienu qed jirċievu ta' bortezomib flimkien ma' dexamethasone (l-istudju open-label ta' Fażi II MMY-2045), ma' riżultati miksuba fil-parti tal-istudju dwar parteċipanti li kienu qed jirċievu monoterapija ta' bortezomib minn studji differenti li fihom il-parteċipanti ntgħażlu b'mod każwali, ta' Fażi
English: CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bzmb=bortezomib; BzmbDx=bortezomib, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio.
Maltese: VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response-rispons parzjali tajjeb ħafna; PR=partial response - rispons parzjali; OR=odds ratio - proporzjon ta' odds * Primary endpoint - Punt aħħari primarju a OR għal rati ta' rispons ibbażati fuq stima ta' Mantel-Haenszel tal-odds ratio komuni għal tabelli stratifikati; valuri p skont it-test ta' Cochran Mantel-Haenszel.
English: b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles
Maltese: b Sa 6 ċikli jistgħu jingħataw lil pazjenti li jiksbu tal-anqas rispons parzjali wara 4 ċikli
English: Based on a population pharmacokinetic analysis, clearance of bortezomib increased with increasing body surface area (BSA).
Maltese: Abbażi ta' analiżi ta' farmakokientika ta' popolazzjoni, it-tneħħija ta' bortezomib żdiedet ma' żieda fl-erja tas-superfiċje tal-ġisem (BSA - body surface area).
English: Such changes may be reversible upon discontinuation of bortezomib (see section 4.8).
Maltese: Ġew irrappurtati każijiet b'mod mhux komuni ta' ostruzzjoni fil-musrana (ara sezzjoni 4.8).
English: Common Herpes zoster (inc disseminated & ophthalmic), Pneumonia*, Herpes simplex*, Fungal infection* Uncommon Infection*, Bacterial infections*, Viral infections*, Sepsis (inc septic shock)*, Bronchopneumonia, Herpes virus infection*, Meningoencephalitis herpetic#, Bacteraemia (inc staphylococcal), Hordeolum, Influenza, Cellulitis, Device related infection, Skin infection*, Ear infection*, Staphylococcal infection, Tooth infection*
Maltese: Infezzjoni*, Infezzjonijiet batteriċi*, Infezzjonijiet virali*, Sepsis (li tinkludi wkoll xokk settiku)*, Bronkopnewmonja, Infezzjoni bil-virus tal-herpes*, Meningoenċefalite erpetika#, Batteremija (anki ta' staphylococcus), Hordeolum, Influwenza, Ċellulite,
English: Malta/Nederland/Norge/Österreich/Portugal/
Maltese: Nederland/Pays-Bas/Niederlande/Нидерландия/Nizozemsko/ Nederlandene/Holland/Ολλανδία/Nizozemska/The Netherlands/Holland/Ολλανδία/ Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/
English: Blood gases abnormal*, Electrocardiogram abnormalities (inc QT prolongation)*, International normalised ratio abnormal*, Gastric pH decreased, Platelet aggregation increased, Troponin I increased, Virus identification and serology*, Urine analysis abnormal*
Maltese: Gassijiet fid-demm anormali*, Anormalità flelettrokardjogramma (li tinkludi żieda fit-titwil tal-QT)*, Proporzjon internazzjonali normalizzat anormali*, Tnaqqis fil-pH tal-istonku, Żieda fl-aggregazzjoni talplejtlits, Żieda fi Troponin I, Identifikazzjoni u seroloġija tal-virus*, Valuri tal-analiżi tal-awrina anormali*
English: Common side effects (may affect up to 1 in 10 people) - shingles (localized including around the eyes or spread across the body) - herpes virus infections - bacterial and viral infections - respiratory infections, bronchitis, coughing with phlegm, flu like illness - fungal infections - hypersensitivity (allergic reaction) - inability to produce enough insulin or resistance to normal levels of insulin - fluid retention - difficulty or problems in sleeping - loss of consciousness - altered level of consciousness, confusion - feeling dizzy - increased heartbeat, high blood pressure, sweating - abnormal vision, blurred vision - heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate - high or low blood pressure - sudden fall of blood pressure upon standing which may lead to fainting - shortness of breath with exercise - cough - hiccups - ringing in the ears, ear discomfort - bleeding from your bowels or stomach - heartburn - stomach pain, bloating - difficulty swallowing - infection or inflammation of the stomach and intestines - stomach pain - sore mouth or lip, throat pain - alteration of liver function - itching of skin - redness of skin - rash - muscle spasms - infection of the urinary tract - pain in limbs
Maltese: Effetti sekondarji komuni (li jistgħu jaffettwaw minn persuna 1 f'10) - ħruq ta' Sant'Antnin (lokalizzat inkluż madwar l-għajnejn jew mifrux madwar il-ġisem) - infezzjonijiet bil-virus tal-herpes - infezzjonijiet batteriċi u virali - infezzjonijiet respiratorji, bronkite, sogħla bil-bili, mard jixbah l-influwenza - infezzjonijiet fungali - sensittività eċċessiva (reazzjoni allerġika) - inkapaċità li tiġi prodotta biżżejjed insulina jew reżistenza għal-livelli normali ta' insulina - żamma tal-fluwidu - diffikultà jew problemi bl-irqad - telf mis-sensi - livell mibdul ta' koxjenza, konfużjoni - tħossok stordut - żieda fit-taħbit tal-qalb, pressjoni għolja, għaraq, - vista mhux normali, vista mċajpra - insuffiċjenza tal-qalb, attakk ta' qalb, uġigħ fis-sider, skumdità fis-sider - pressjoni għolja jew baxxa - pressjoni li tinżel f'daqqa waħda malli tqum bilwieqfa li tista' twassal għal ħass ħażin - qtugħ ta' nifs meta tagħmel l-eżerċizzju - sogħla - sulluzzu - żarżir fil-widnejn, skumdità fil-widnejn - ħruġ ta' demm minn imsarnek jew mill-istonku tiegħek - ħruq ta' stonku - uġigħ fl-istonku, nefħa fl-istonku - diffikultà biex tibla' - infezzjoni jew infjammazzjoni tal-istonku u l-imsaren - uġigħ fl-istonku - ħalq jew xufftejn misluħin, uġigħ fil-gerżuma - bidla fil-funzjoni tal-fwied - ħakk fil-ġilda
English: In dogs, the decreased cardiac contractility and hypotension responded to acute intervention with positive inotropic or pressor agents.
Maltese: Filklieb, it-tnaqqis fil-kapaċità kardijaka tal-kontrazzjoni u ipotensjoni, irrisponda għal intervent akut b'sustanzi inotropiċi pożittivi jew pressor.
English: Common Gastrointestinal haemorrhage (inc mucosal)*, Dyspepsia, Stomatitis*, Abdominal distension, Oropharyngeal pain*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*, Flatulence
Maltese: Emorraġija gastrointestinali (anki tal-mukoża)*, Dispepsija, Stomatite*, Distensjoni addominali, Uġigħ orofarinġeali*, Uġigħ ta' żaqq (li jinkludi wġigħ gastrointestinali u tal-milsa)*, Disturb orali*, Gass
English: An odds ratio (OR) > 1 indicates an advantage for BzmbR-CAP. f Include all CR+CRu, by IRC, bone marrow and LDH.
Maltese: Proporzjon ta' probabbiltà (OR - odds ratio) > 1 jindika vantaġġ għal BzmbR